Status:
COMPLETED
Efficacy and Safety Study of Fluvastatin and Ezetimibe Combined Versus Fluvastatin Alone
Lead Sponsor:
Novartis
Conditions:
Dyslipidemia
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The objective of this study is to assess the effect of the combination treatment on C-reactive protein and inflammatory markers as well as the safety and tolerability in a Spanish population
Eligibility Criteria
Inclusion
- Patients aged 18-75 Primary hypercholesterolemia Signed informed consent
Exclusion
- Patients involved in clinical trials 3 months prior to inclusion Patients treated with drugs specified in protocol Fertile women not using contraceptive methods
- Other protocol defined in and exclusion criteria may apply
Key Trial Info
Start Date :
August 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2005
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT00171288
Start Date
August 1 2003
End Date
August 1 2005
Last Update
November 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
Madrid, Spain